We are live on ! Find out more
ANIX icon

Anixa Biosciences

22 hedge funds and large institutions have $5.53M invested in Anixa Biosciences in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

24% more capital invested

Capital invested by funds: $4.44M → $5.53M (+$1.09M)

5% more funds holding

Funds holding: 2122 (+1)

0.11% less ownership

Funds ownership: 7.68%7.57% (-0.11%)

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
8
Reduced
6
Closed
4
Calls
Puts
Net Calls
Net Calls Change

ANIX Hedge Fund Activity: Q4 2020 in Review

22 of the 5,675 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q4 2020, worth a combined $5.53M — up 24% from $4.44M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ANIX positions and 4 closed out — a net gain of 1 holder — while 8 added to existing stakes and 6 trimmed.

The largest buyer was UBS Group, adding an estimated $227K. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $147K.

  • 22 institutional investors held Anixa Biosciences (ANIX) as of Q4 2020, up from 21 in Q3 2020.
  • Funds reported $5.53M of Anixa Biosciences stock for Q4 2020, up 24% quarter-over-quarter.
  • 5 funds opened new Anixa Biosciences positions in Q4 2020 and 4 closed out, a net change of +1 holder.
  • The largest Anixa Biosciences buyer in Q4 2020 was UBS Group, an estimated $227K added.
  • The largest Anixa Biosciences seller in Q4 2020 was Qube Research & Technologies (QRT), an estimated $147K sold.

Based on aggregated 13F filings for Q4 2020.